trending Market Intelligence /marketintelligence/en/news-insights/trending/20oEaXHbmzRh-QdrDk-gSw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Teva downgraded by Moody's on concerns over debt reduction

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Teva downgraded by Moody's on concerns over debt reduction

Moody's downgraded the senior unsecured ratings of Teva Pharmaceutical Industries Ltd. and its units to Baa3 from Baa2.

The rating agency maintained the rating outlook at negative.

The downgrade reflects the slower progress of deleveraging than the agency expected, as Teva faces weakness in its U.S. generics business and the threat of generic competition on its multiple sclerosis treatment Copaxone, said Morris Borenstein, a Moody's assistant vice president.

Borenstein added the agency believes debt/EBITDA will remain elevated above 4x over the next 18 months, while pricing pressure and delays in new product launches will continue to be headwinds in the U.S. generics business through 2018.

The negative outlook reflects Moody's view that Teva's rating will remain pressured over the next 12 to 18 months due to these concerns.

Moody's also believes that earnings and cash flow will contract in 2018.

Teva's Baa3 rating reflects its notable scale, global diversity and position as the world's largest generic drug company, as well as one of the largest manufacturers of active pharmaceutical ingredients. It is also supported by the company's strong cash flow. The rating is constrained by the company's high financial leverage and high profit concentration in Copaxone.

Moody's said it believes that Teva is committed to deleveraging as signified by the 75% reduction of its quarterly dividend. The dividend cut, together with asset sale proceeds, will support debt repayment over the next 12 months but the pace of deleveraging is uncertain, the rating agency added.